Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
DPV-001 is a cancer vaccine consisting of dendritic cell targeting microvesicles (DRibbles), which are autophagosomes derived from two non-small cell lung carcinoma cell lines (UbiLT3 and UbiLT6) that contain numerous tumor-associated antigens, including DAMPs, and delivers stable short-lived proteins (SLiPs) and defective ribosomal products (DRiPs), potential resulting in the induction of antitumor immune response (JITC 2015; 3(Suppl 2): P435; JITC 2013; 1(Suppl 1): P260).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|DPV-001 + INCAGN01876 + Retifanlimab||DPV-001 INCAGN01876 Retifanlimab||0||1|
|DPV-001 + Retifanlimab||DPV-001 Retifanlimab||0||1|